Susana Ayesa Alvarez

Senior science researcher

Biography

Master of Science in Chemistry (1993, University of Zaragoza) and Ph.D. in Chemistry (Organic Chemistry, 2008, University of Stockholm). She received a COMETT Grant (1993-1994, Brussels) to work at the international pharmaceutical company Pharmacia (Stockholm) in the optimization of the synthetic process of the drug Fragmin® obtaining later on a permanent position as a research scientist in the department of medicinal chemistry.

During her time at Pharmacia (1994-2000) she worked in several research projects in the field of metabolic diseases, being a pioneer in Sweden in the field of combinatorial chemistry. At the beginning of 2000 she moved to the Swedish company Medivir where she is at the moment, working as a senior research scientist and team leader in the chemistry department. Her research has been mainly focused in the field of Hepatitis C, where she has carried out the design and synthesis of inhibitors of the serine protease HCV NS3/4A, work that culminated in the discovery of simeprevir (Olysio®), currently approved drug for the treatment of Hepatitis C, as a result of a research collaboration between Medivir and Janssen Pharmaceuticals.

Additionally Susana has been researching in the inhibition of polymerases and proteases of several other viruses as well as inhibitors of human proteases, such as the cysteine protease Cathepsin S as therapeutic treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain. She is the co-inventor of 14 patent applications whereas 8 of them granted. Since 2013 she has a position as employee representative director at the Medivir board of directors, taking part of the of the work done at the research committee.